Download Files:
Gln-AMS (TFA)
$550 – $3,950
Products Details
Product Description
– Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM.
Web ID
– HY-112861A
Storage Temperature
– -20°C (Powder, stored under nitrogen)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H23F3N8O10S
References
– [1]Rath VL, et al. How glutaminyl-tRNA synthetase selects glutamine. Structure. 1998 Apr 15;6(4):439-49.|[2]Fang P, et al. Structural basis for full-spectrum inhibition of translational functions on a tRNA synthetase. Nat Commun. 2015 Mar 31;6:6402.
Molecular Weight
– 588.47
Compound Purity
– 98.73
SMILES
– NC1=C2N=CN([C@@H]3O[C@H](COS(=O)(NC([C@@H](N)CCC(N)=O)=O)=O)[C@@H](O)[C@H]3O)C2=NC=N1.OC(C(F)(F)F)=O
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 130 mg/mL (ultrasonic)
Target
– Aminoacyl-tRNA Synthetase;Bacterial
Pathway
– Anti-infection;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
